Virus attenuation by genome re-encoding is a pioneering approach for generating effective live-attenuated vaccine candidates. Its core principle is to introduce a large number of synonymous substitutions into the viral genome to produce stable attenuation of the targeted virus. Introduction of large numbers of mutations has also been shown to maintain stability of the attenuated phenotype by lowering the risk of reversion and recombination of re-encoded genomes. Identifying mutations with low fitness cost is pivotal as this increases the number that can be introduced and generates more stable and attenuated viruses. Here, we sought to identify mutations with low deleterious impact on the in vivo replication and virulence of yellow fever virus (YFV). Following comparative bioinformatic analyses of flaviviral genomes, we categorized synonymous transition mutations according to their impact on CpG/UpA composition and secondary RNA structures. We then designed 17 re-encoded viruses with 100-400 synonymous mutations in the NS2A-to-NS4B coding region of YFV Asibi and Ap7M (hamster-adapted) genomes. Each virus contained a panel of synonymous mutations designed according to the above categorisation criteria. The replication and fitness characteristics of parent and re-encoded viruses were compared in vitro using cell culture competition experiments. In vivo laboratory hamster models were also used to compare relative virulence and immunogenicity characteristics. Most of the re-encoded strains showed no decrease in replicative fitness in vitro. However, they showed reduced virulence and, in some instances, decreased replicative fitness in vivo. Importantly, the most attenuated of the re-encoded strains induced robust, protective immunity in hamsters following challenge with Ap7M, a virulent virus. Overall, the introduction of transitions with no or a marginal increase in the number of CpG/UpA dinucleotides had the mildest impact on YFV replication and virulence in vivo. Thus, this strategy can be incorporated in procedures for the finely tuned creation of substantially re-encoded viral genomes.
Introduction
amongst synonymous codons is highly non-random in the genome of viruses, they hypothesised that this equilibrium could be modified in a manner that should be relatively detrimental to virus replication. They provided the first evidence supporting this concept by introducing slightly detrimental synonymous codons within the encoding region of the poliovirus genome, i.e. without modifying the encoded proteins after which they observed a decrease in viral replication capacity. This codon re-encoding strategy bypasses the limitations of empirical attenuation methods: importantly, the high number of mutations involved decreases the risk of reversion of the attenuating mutations and reduces the likelihood of vaccine strain recombination (with either vaccine or wild-type viruses). The use of silent mutations also lowers the risk of emergence of untoward biological properties.
The first rationale for codon usage bias was that codon abundance correlated with that of isoaccepting tRNAs and could influence the level of protein production within a given host (37) . Several other possibilities have been proposed since then, including implication in mRNA structure and its folding (38, 39) , microRNA-targeting (40, 41) and enhanced recognition by the immune system (42) , that may vary according to the host (43, 44) . Specific and random reencoding approaches have been efficiently applied to several human RNA viruses including poliovirus, influenza A virus, human immunodeficiency virus, respiratory syncytial virus, chikungunya virus (CHIKV), JEV, TBEV and DENV (35, 36, (45) (46) (47) . Considering a major role of genome-wide mutational processes in the shaping of synonymous sites (48) , specific reencoding approaches include codon and codon-pair deoptimization as well as increase of CpG/UpA dinucleotide frequency. On the other hand, the efficiency of random codon reencoding strategies for the attenuation of CHIKV in vitro and of TBEV in vivo suggests an important influence of local constraints (e.g. cis-acting sequences, miRNA targeting) on genome encoding (45, 46, 49, 50) .
Much remains to be learned to understand the multiple mechanisms that shape synonymous codon usage and its contribution to the attenuation process during re-encoding. In this exploratory work, we defined several types of silent mutations and sought to identify which one(s) had the least detrimental impact on viral replicative fitness. In the future, such silent changes could be introduced in large numbers along the genome of vaccine candidates. YFV provides a suitable experimental model because (i) the virus can be produced conveniently and modified using the Infectious Subgenomic Amplicons (ISA) reverse genetics method (51) and (ii) an excellent animal model of infection exists in juvenile Syrian Golden hamsters, to enable the comparison of wild-type and re-encoded strains in vivo. This model was established in our laboratory using the Asibi-derived, YF Ap7M strain (Klitting et al., accepted manuscript) (52) derived from the previously described hamster-virulent YF Asibi/hamster p7 strain (47) .
When inoculated into hamsters, both strains induce a disease with features close to that of the human disease.
Starting with a bioinformatic analysis of flaviviral genomes, we defined several types of mutations and used them for the design of 8 re-encoded sequences. The re-encoded viruses were derived from the wild-type Asibi strain and the hamster-adapted Ap7M strain, with which they were compared both in vitro and in vivo through fitness assays, infection assays and complete genome deep-sequencing. Although only the most heavily re-encoded virus (741 mutations) showed an observable decrease in replicative fitness in vitro, a range of attenuation levels was observed for the re-encoded variants when tested in vivo. The lowest impact was observed for strains that were re-encoded with transitions that did not include new CpG/UpA dinucleotides. In addition, we showed that the strains with the most attenuated phenotypes in vivo could induce robust protective immunity in hamsters following challenge with the lethal YF Ap7M virus.
Results
The results of the in silico analysis that served as a basis for the design of the re-encoded strains are provided in the Supplementary Results S2 section.
Design strategies for re-encoded strains Framework design. Previous analyses on the impact of random codon re-encoding on chikungunya (CHIKV) and tick-borne encephalitis (TBEV) viruses, were used as a starting point to obtain observable in vitro and/or in vivo attenuation. Nougairède and colleagues observed a decrease in CHIKV replicative fitness in vitro, using 264 to 882 mutations located within the NSp1, NSp4 and/or envelope protein encoding regions (45) . Clear in vivo attenuation of TBEV was achieved by de Fabritus and colleagues using as few as 273 mutations located in the NS5 coding region (46) .
Based on those results, we defined a framework for the design of YFV re-encoded strains. For each variant, we used a maximum of 350 synonymous mutations (ca. 1 change for every 10 nucleotides). We chose to re-encode the region located within the coding sequences of proteins NS2A to NS4B, so that re-encoding would not affect the structural proteins, the viral RNA-dependent RNA polymerase, or the highly structured, 5' and 3' ends of the genome. The highly re-encoded variant rTs4 was reconstructed by the addition of 388 synonymous mutations in the NS5 encoding region. In all cases, the structural proteins encoding sequence remained unchanged, which was an advantage as the production of hamster-virulent YFV variants required the use of a modified E protein sequence. To lower the risk of major detrimental effects of re-encoding (e.g. disruption of cis-acting sequences), we analysed an alignment of 35 YFV complete coding sequences (CDS) and defined only synonymous sites for which at least one mutation could be observed as eligible for re-encoding. These will be referred to as "editable sites". Finally, we avoided creating or removing any rare codons during the re-encoding process (see definition in Supplementary Protocols S1).
Re-encoding strategies. Following in silico analysis of flaviviral genomes, we defined two major types of synonymous mutations (see below). The creation of additional TCG trinucleotide patterns was considered a "specific" type of mutation. In the genus Flavivirus, TCG trinucleotides are frequent in Insect-Specific Flavivirus (ISF) genomes and sparse in both No Known Vector virus (NKV) and arbovirus genomes (see Supplementary results). In addition, this pattern may enhance the innate immunity in vertebrate cells, as suggested by Greenbaum, Jimenez-Baranda and colleagues (43, 53) . "Specific" mutations also included the creation of CpG and UpA dinucleotides, which were the least frequently introduced dinucleotides (CpG and UpA) in YFV species (see Supplementary results). This is in accordance with the previous observation of dinucleotide bias in the genomes of many viruses, in a fashion that was suggested to, at least partly, mirror the dinucleotide usage of their host(s) (54, 55) . In vertebrates, CpG dinucleotide bias is commonly seen as the consequence of cytosine methylation-deamination (56) (57) (58) and the detection of such patterns may be a part of the hostdefence mechanism against non-self RNA (59) (60) (61) . The introduction of CpG and UpA dinucleotides has been frequently used in re-encoding studies (42, (62) (63) (64) . By contrast, "nonspecific" types of mutations did not cause any increase in CpG/UpA dinucleotides. This category includes transitions located on and outside sites associated with the putative secondary structures identified in the YFV genome during in silico analysis (see Supplementary results). All mutation types defined in this study are described in Table 1 . Design. In total, 9 re-encoded viruses were designed based on the Asibi strain sequence.
Aside from the highly re-encoded rTs4 virus, all Asibi-derived re-encoded viruses were designed with 100 to 400 mutations located between positions 3,924 and 6,759 of YF Asibi complete coding sequence (CDS). First, YFV rTs3 was designed by introducing exclusively "simple" transitions (siTs) into the target region, within the CDS of the reference strain Asibi (AY640589). The term "simple" refers to synonymous, non-specific (no CpG/UpA introduction) mutations located outside putative secondary structures. YFV rTs3 included 353 substitutions, i.e., the highest possible number that could be introduced into the target region. All other reencoded viruses except YFV rTCG were designed starting from the rTs3 virus by (i) reverting some of the siTs back to the original sequence (rTs1, rTs2), or (ii) substituting some of the siTs for a different type of mutation (rUA, rCG, rSS and rN). The rationale for this design procedure was to obtain viruses that could be compared one to another, as they would share a common background of mutations.
Overall the 9 initial re-encoded viruses were designed as follows:
 YFV rTs1, rTs2 and rTs3, include increasing numbers of "simple" transitions (siTs).
 YFV rSS includes non-specific transitions on sites corresponding to putative secondary structures (SII-Ts).
 YFV rUA and rCG include transitions leading to an increase in the number of UpA or CpG dinucleotides into the viral sequence (UA-and CG-Ts), respectively.
 YFV rN includes both transitions and transversions, some of which lead to the introduction of 83 UpA and 54 CpG dinucleotides into the viral sequence.
 YFV rTCG includes transitions leading to an increase in the number of TCG dinucleotides into the viral sequence (TCG-Ts). Importantly, this strain was not derived from rTs3 and exclusively includes TCG-Ts.
 YFV rTs4 includes 388 additional siTs that were introduced into the genome of rTs3 virus, between positions 6,846 and 9,765 (in CDS). 
Figure 1. Subgenomic fragments used for wild-type and re-encoded virus production using the Infectious Subgenomic Amplicon method. *For
Ap7M strain and hamster-adapted re-encoded strain (Ap7M-derived) production, the subgenomic fragment FIAp7 was amplified from the corresponding plasmid and combined to subgenomic fragments FII (wild-type or re-encoded) and FIII (wild-type). **For each of the YFV re-encoded strains (both Asibi and Ap7Mderived) production, a different subgenomic fragment FII was amplified from the corresponding plasmid. ***For the production of YFV re-encoded strain rTs4, the subgenomic fragment FIIIR was amplified from the corresponding plasmid and combined to fragments FI (wild-type) and FII (re-encoded).
In vitro behaviour of YFV re-encoded strains
All the strains used in this study (1 WT, 1 hamster-adapted and 17 re-encoded) were produced using the ISA method, as detailed in Fig 1 and in the "Material and Methods" section.
Sequence analysis. Next Generation Sequencing (NGS) was performed on the cell culture supernatant media (viral stocks i.e., after 3 passages). For all viruses, both the integrity of the genome and the intra-population genetic diversity were assessed on the CDS. At the level of intra-population genetic diversity, a variant subpopulation (further referred to as "variant") was regarded as major when its corresponding nucleotide proportion (CNP) was over 75%. Only consensus mutations associated with major variants were considered for further analysis. All sequencing results are shown in Tables 3 and 4 .
During virus production, sequence variability could arise as an artefact of the production method itself (PCR amplification of DNA fragments) and as the result of the adaptation of reencoded strains to culture conditions.
No consensus mutation associated with a major variant was identified in the genome of the parent strain YFV Asibi, which only included twelve minor variants. In re-encoded genome sequences, low numbers of consensus mutations were observed, ranging from 0 to 6, with a mean of 2 consensus changes/virus and 39% of non-synonymous (NS) mutations on average.
Consensus mutations were equally distributed between re-encoded and non-re-encoded regions and, nearly no convergence was observed between viral sequences. Only two viral sequences (YFV rTs2 and rCG) had consensus mutation reversions. One was common to both strains and corresponded to a siTs mutation (C to T), at CDS position 5,430. The two others were also siTs mutation reversions (C to T and A to G, respectively), located at CDS positions 5,442 and 5,667 of YFV rTs2 and rCG, respectively. The absence of consensus NS change in the sequence of the original Asibi strain and the very limited convergence between viral sequences are in accordance with the low number (3) of in cellulo passages. This strongly suggests that the consensus mutations observed in viruses YFV rTs3, rCG, rSS and rTCG did not result from selective pressure due to culture conditions but may be artefacts of the production method.
The total numbers of variants, per virus, ranged from 1 to 16, with a mean of 9 variants per virus. Interestingly, variants were most frequently observed outside the re-encoded regions (75% of variants outside the re-encoded regions), similar to what was observed for the parental sequence, (92% of variants outside the re-encoded region). The low number of reversions and the limited sequence variability at re-encoded sites accord with previous work showing that reencoded CHIKV strains evolved mostly through compensatory mutations rather than mutation reversions (45).
In vitro replicative fitness. The infectious titre was estimated using a TCID50 assay in BHK21 cells for both Asibi and Asibi-derived re-encoded strains using infectious cell supernatant medium (viral stock) (results detailed in Table 2 ). The maximal infectious titre was observed for the wild-type strain Asibi (10 8 TCID50/mL). A 1 to 2-log decrease was observed for most re-encoded strains, with infectious titres ranging between 2.10 6 and 4.10 7 TCID50/mL. However, the least re-encoded virus, YFV rTs1 (101 mutations), was unexpectedly endowed with a remarkably low infectious titre (4.10 5 TCID50/mL) whilst the most re-encoded virus, YFV rTs4 (741 mutations), exhibited the lowest infectious titre (6.10 3 TCID50/mL).
For each of the re-encoded viruses, the replicative fitness was compared to that of the wildtype strain using competition assays. Specific virus detection was achieved for one in two passages using next generation sequencing (NGS) methods by amplifying a 256 nucleotide region and counting virus-specific patterns within the read population. For all re-encoded viruses except rTs4 (≤ 353 mutations), replicative fitness in vitro was comparable to that of the Asibi strain: in all competitions, both competing viruses could still be detected at the 10 th passage (see Fig 2) . By contrast, the highly re-encoded rTs4 virus (741 mutations) showed a were calculated as a mean for the 3 replicates. For each replicate, the pattern count is the mean count for the three virus-specific patterns. Each specific pattern count is the sum of the sense and reverse patterns counts within a given read population (obtained through NGS sequencing). 
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Note: For each virus, the consensus changes found in the CDS from the viral stock are detailed above. The expected sequence refers to that of plasmids that served for subgenomic fragment amplification while producing viruses using the ISA method. Only consensus mutations associated with major variants (CNP>75%) are described. Amino Acid (AA) positions are given with reference to the beginning of mature protein sequence (ie. AA position 107 in prM, written prM 107, corresponds to AA position 228 within the precursor polyprotein). A detailed map of protein positions within the YFV polyprotein sequence is provided in the supplementary Table S11 . Note: Counts of consensus mutations and variant subpopulations are presented as raw numbers. Consensus reversion mutations were defined with reference to YFV strain Asibi. The coverage depth has been calculated given that the total length of YFV CDS is 10,236 nt. No variant was taken into account with a coverage lower than 1000 reads. No consensus mutation was taken into account with a coverage lower than 50 reads.
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clear reduction in replicative fitness and could not be detected after the 5 th passage.
In vivo behaviour of YFV re-encoded strains
The infectious titres of viral stocks for Ap7M and Ap7M-derived re-encoded strains were established in BHK21 cells, using a TCID50 assay (results detailed in Table 2 ). For the majority of re-encoded viruses, no notable difference was observed with the parent strain Ap7M (9.10 8 TCID50/mL), with infectious titres ranging from 4.10 8 to 6.10 8 TCID50/mL. However, viruses YFV rNh and rTCGh showed a 1 to 2-log reduction in viral titre (6.10 6 and 6.10 7 TCID50/mL, respectively).
Sequence analysis.
NGS was performed on the viral stocks for all Ap7M-derived re-encoded viruses as described in the previous section (results shown in Tables 4 and 5 ).
As observed for Asibi-re-encoded viruses, the number of consensus mutations associated with major variants were low, ranging from 0 to 5, with a mean number of 1 consensus change/virus and 59% of non-synonymous mutations on average. Consensus mutations were mainly distributed outside re-encoded regions (90%), with no reversion. As observed for Asibi, the parent Ap7M strain showed no NS consensus sequence changes associated with major variants. Moreover, the re-encoded viruses which were given a limited number of in cellulo passages did not exhibit any evidence of convergent evolution. Based on this evidence, the consensus mutations observed in YFV rTs3h, rNh and rTCGh are likely to be artefacts of the production method rather than the result of adaptation of re-encoded viruses to culture conditions. Notably, for YFV rTs3h, the consensus NS change observed in the inoculum was not essential for virus survival in vivo as it was not maintained following infection in hamsters.
The total number of variants per virus varied among strains, ranging from 4 to 22, with a mean Normalized percentages of initial weight (%IW) (A), viral loads at 3/6 dpi (B), as well as mortality rates (C), are illustrated for all viruses. %IW were evaluated on groups of 12 and 9 hamsters at 3 and 6 dpi, respectively. Viral loads were evaluated on groups of 3 and 4 hamsters at 3 and 6 dpi, respectively. Of note, for YFV rTs2h, only 3 hamsters were used for viral load determination at 6 dpi. Mortality rates were evaluated on groups of 5 hamsters for all viruses, apart from rTs2h, for which 6 hamsters were used. Computations of %IW and viral loads are detailed in the corresponding paragraphs within the Materials and Methods section. Significant %IW and viral load differences observed between Ap7M and the other viruses at 6 dpi (Wilcoxon rank-sum test p-value <0.05) are indicated by a star (*). The ranges corresponding to viral load values recorded at 3 and 6 dpi during Ap7M infection are highlighted by light (3 dpi) and dark (6 dpi) blue rectangles. Nearly all hamsters inoculated with Ap7M strain developed outward signs of illness such as ruffled fur, prostration, dehydration and lethargy. One hamster did not show any sign of illness, both its liver and blood were tested negative for YFV genomes and it was excluded from analysis. A high mortality rate (80%) was observed, similar to previous observations (52) .
Clinical signs of the disease appeared as early as 4 dpi and all animals died within 2/3 days after onset of the symptoms. Weight loss was not observed at 3 dpi (mean of %IW: 97%), but between 3 and 6 dpi, significant weight losses were recorded (mean of %IW: 71%, Wilcoxon 
Note: For each virus, the consensus changes found either in the complete coding sequence from the viral stock or in partial sequences from infected hamster liver homogenates are detailed above. The expected sequence refers to that of plasmids that served for subgenomic fragment amplification while producing viruses using the ISA method. For 1 st and 2 nd variant descriptions, capital letters correspond to variant proportions above 75%, lowercase letters to variant proportions between 6 and 75% and dashes to variant proportions below 5%. Amino Acid (AA) positions are given with reference to the beginning of mature protein sequence (i.e. AA position 107 in prM, written prM 107, corresponds to AA position 228 within the precursor polyprotein). A detailed map of protein positions within the YFV polyprotein sequence is provided in the supplementary Table S11. rank sum test, p-value = 0,00032). All livers were found to be YFV-positive by qRT-PCR, with viral RNA loads ranging between 6.10 7 and 6.10 9 RNA copies per gram of liver and no significant difference between the viral yields at 3 and 6 dpi (Wilcoxon rank sum test, pvalues >0,05). No consensus change was detected in the viral sequence after propagation in hamsters.
A reduction in mortality rate was observed in all groups infected with re-encoded viruses. For most (YFV rTs1h, rUAh, rCGh, rSSh, rNh and rTCGh), the reduction was significant (Logrank test, p-values=0,03960 in all cases), as no hamsters died. However, for YFV rTs2h and rTs3h, mortality was reduced but still observed (17 and 20%, respectively; Logrank test, p-values=0,05820 and 0,07186). Evaluation of the phenotypic impact of re-encoding. Some conclusions can be drawn by analysing the in vivo phenotypes of re-encoded viruses in light of the sequencing data obtained from infected hamsters liver samples (see details in Table 5 ). For example, the sequences obtained from the livers of hamsters infected with the control strain Ap7M did not include consensus mutations. This indicates that the sequence of the parent virus was stable under the experimental conditions and that adaptative mutations were not required for efficient replication in vivo.
Regardless
Impact of "non-specific" re-encoding strategies. In general, low detrimental effects resulted from the introduction of simple transitions (siTs) (i.e., with no modification of predicted secondary structures) on the in vivo phenotype of YFV. Strain rTs2h (247 siTs) was associated with mild attenuation in vivo, with a decreased mortality rate and a reduction in hamster weight loss at 6 dpi but no significant change in the production of viral RNA (Wilcoxon rank sum, p-values>0,05). As the viral sequence remained unchanged during the course of the experiments, the in vivo phenotype can be interpreted as being the result of genome reencoding. rTs3h (353 siTs) and rTs1h (101 siTs) viruses, respectively showed mild and strong attenuation in vivo. For both, consensus NS mutations associated with major variants arose during the in vivo infections possibly resulting from adaptation of the re-encoded viruses to the in vivo conditions during the infection. However, they did not correspond with the recovery of an in vivo phenotype similar to that of the parent strain Ap7M. Surprisingly, the least reencoded strain, rTs1h (101 siTs) was more attenuated in vivo than the rTs2h strain, that included all rTs1h mutations plus 146 additional siTs. We observed a mild detrimental impact following the introduction of transitions at sites involved in predicted RNA secondary structures.
The sequence of strain rSSh involved siTs as well as transitions located on predicted secondary RNA structures and remained stable throughout the in vivo experiments. The variant showed a partially attenuated phenotype in vivo (complete loss of mortality, no alleviation in weight loss or viral loads) that can thus be attributed to this second re-encoding strategy. Overall, these results illustrate the relative efficiency of the use of "non-specific" transitions in providing a stable re-encoded infectious genome exhibiting in vivo attenuation. Finally, for strain rNh, consensus NS mutations were identified in the sequences from both the inoculum and hamster liver samples. It is therefore complicated to determine which of the consensus changes were production artefacts or resulted from adaptation of the virus to in vitro or in vivo conditions. Nevertheless, the virus exhibited a strongly attenuated phenotype in vivo (no mortality, alleviated weight loss and viral loads) indicating that, regardless of the emergence of the -potentially compensatory-consensus NS mutations, the combination of several re-encoding strategies led to an important degree of attenuation considering the low number of mutations used for re-encoding (i.e., 233).
Impact of "specific
Adaptation of re-encoded viruses through consensus NS mutations. Altogether,
these results indicate that consensus mutations can arise and stably establish in re-encoded viruses in response to in vivo conditions. This was observed for most of the re-encoded viruses, notably some with as few as 101 re-encoded sites (rTs1h) or as many as 353 re-encoded sites (rTs3h). In most cases, the consensus mutations did not lead to a full recovery of in vivo viral replicative fitness. Observable changes in the biological properties of the viruses (e.g. change in tropism, as reported for YF strain 17D), were not reported in any of the viruses that exhibited consensus NS mutations.
Immunisation potential of YF-re-encoded strains: serological investigations. For each of the re-encoded viruses that showed complete loss of mortality in vivo, sera were recovered from infected hamsters at 16 dpi during the comparative study of pathogenicity (see above). Sera from both uninfected hamsters and vaccinated humans were included as negative and positive controls, respectively. Neutralisation tests were performed using serial fivefold dilutions of all sera, the YF Ap7M challenge virus and BHK21 cells. Neutralising antibodies were detected in both hamsters infected with YF-re-encoded viruses (NT50 ranging between 2.10 -3 and 1.10 -5 ) and in a control group of 17D-vaccinated humans (NT50 between 4 and 5.10 -4 ) whilst the negative control group did not show any neutralisation activity against
Ap7M (see Fig 4) .
Immunisation potential of YF-re-encoded strains: challenge experiments.
Two groups of 11 three-week-old female hamsters were inoculated intraperitoneally with 5.10 5 TCID50 of virus (either YFV rCGh or rNh). A negative control group of 9 hamsters was not immunised before the challenge and a control group of 2 uninfected hamsters was included for monitoring hamster weight.
Unexpectedly, one hamster from the YFV rCGh infected group died at 6 dpi, although it did not show any symptom nor weight loss. Its liver was tested positive for YFV. Twenty-four days after inoculation, 2 and 3 hamsters from rCGh and rNh groups, respectively, and a hamster from the non-infected group were euthanised and both serum and liver samples were recovered for neutralisation assay and viral load determination. For all 3 groups, the 8 remaining hamsters were inoculated intraperitoneally with 5.10 5 TCID50 of virus (Ap7M). Two hamsters were euthanised at 3 and 6 days post-challenge (dpc) to conduct virology investigations from liver samples whilst 4 were kept for evaluating mortality rate (endpoint in case of survival: 12 dpc). In agreement with previous observations, no mortality was observed post-challenge in either immunised or control groups, indicating that mortality rate in hamsters decreases importantly in adults (>6-week-old) individuals (9) . However, there was a great difference in the evolution of viral loads, with no increase in viral yields at 3 and 6 dpc in rCGh and rNh immunised animals while high viral loads were detected in the control animals, around ~10 9 RNA copies/g of liver.
Evidence of protection was also provided by the fact that there was no weight loss in immunised groups at 6 and 10 dpc, whereas a significant weight loss up to 18% at 10 dpc (Wilcoxon rank sum test p-value=00239) was recorded in the control group. Altogether, these results indicate efficient immunisation of hamsters inoculated with YFV re-encoded strains rCGh or rNh. 
Discussion
Genome re-encoding through synonymous codon replacement is a recognised procedure for attenuating RNA viruses including poliovirus, influenza virus, respiratory syncytial virus, chikungunya virus, tick-borne encephalitis virus and dengue virus (35, 36, (45) (46) (47) . Additional insights into the mechanisms contributing to attenuation of the virus phenotype following synonymous codon replacement should prove valuable for the custom design of, viable, safe, cost-effective vaccine candidates. The initial purpose of this work was to identify the types of synonymous mutations that would impose the least detrimental effect on viral replicative fitness. Previous codon re-encoding studies in our laboratory were achieved for two other arboviruses, CHIKV and TBEV (45, 46) . In the light of this experience, we planned an exploratory study of the effects of re-encoding on both the in vitro and in vivo phenotypes of yellow fever virus (YFV). Our choice was motivated by the availability of a suitable reverse genetics system for re-encoded strains of YFV production, viz., the ISA method (51)) and a robust YF hamster model (69) . Hence, we could test first the in vitro, and then the in vivo replicative fitness of our strains before using some of the live-attenuated candidates for hamster immunization studies.
Here, we have described the direct impact of synonymous substitutions on YFV replicative phenotype both in vitro and in vivo. As previously described with TBEV (46), the level of reencoding necessary to observe viral attenuation in vivo was lower than that required to obtain an observable decrease in replicative fitness in vitro. As further suggested by supplementary, basic, growth curve experiments (data not shown), all re-encoded strains with only one reencoded fragment (101-350 mutations) maintained a replicative phenotype close to that of the parental Asibi strain in vitro. Only YFV rTs4, that included an additional re-encoded fragment (741 mutations in total), showed a severe reduction in replicative fitness in vitro. Previous works on Poliovirus, Echovirus, RSV, Influenza, HIV, CHIKV, DENV and Marek's disease virus (35, 45, 63, (70) (71) (72) (73) (74) brought evidence that the effect of synonymous mutations may vary according to the location within the viral sequence. Hence, a control, Asibi-derived virus including only the additional re-encoded fragment (388 mutations in the NS5) was produced. Contrarily to the viruses re-encoded in the NS2-3-4 region, it showed a decrease in replicative fitness during competition experiments (outcompeted by the wild-type virus at passage no. 10). As three consensus non-synonymous mutations (associated to major variants) arose in the viral sequence during the production of this virus, it is not possible to associate the in vitro phenotype to the re-encoding in the NS5 protein rather than to the additional, consensus, non-synonymous mutations. However, this suggests that in the case of YFV, re-encoding may have a greater effect in the polymerase gene than in other non-structural proteins. In contrast with the in vitro results, we observed a broad range of levels of attenuation amongst all the strains that were tested in hamsters (101-350 mutations). Whilst the least attenuated viruses showed no observable loss of replicative fitness and retained a degree of lethality, the most attenuated viruses displayed a complete loss of lethality, together with a tenfold reduction in viral loads in the liver and significant alleviation of weight loss. We did not produce nor test a hamsteradapted version of the rTs4 strain because such a heavily re-encoded virus would have been unlikely to achieve infection in vivo.
In contrast with previously published re-encoding studies, we performed deep sequencing of infected hamster liver homogenates to correlate precisely each viral sequence(s) with the observed phenotype. Our results indicate that, detailed genetic information and in particular, that retrieved from in vivo experiments, is critical to determine the significance of synonymous substitutions within the attenuation process. When monitoring the evolution of YFV re-encoded strains after production (i.e., transfection followed by 3 passages in vitro) or after one passage in hamsters, we observed the spontaneous emergence of both synonymous and non-synonymous substitutions. These consensus changes may be artefacts of the production methods employed (PCR amplification of DNA fragments, stochastic evolution events) or they may have resulted from the adaptation of re-encoded viruses to the differing in vitro and in vivo conditions of replication. In some cases, we observed the emergence of consensus non-synonymous mutations present in major variants of the viral stock used as the inoculum for in vivo experiments. For these viruses, the analysis of the results from in vivo experiments and attempts to correlate them with sequencing data was limited due to consensus NS mutations which impeded the identification of the specific impact of silent mutations on the viral phenotype in vivo.
Several conclusions can be drawn regarding the in vivo phenotypic impact of the different strategies used to produce re-encoded YFV strains. Rather, role(s) in finely tuning the efficiency of translation (mRNA or co-translational folding) or in interactions with viral, and non-viral proteins have been proposed (38, 39, 78) .
Previous studies have shown that increase in CpG/UpA dinucleotides is an efficient attenuation mechanism (42, 62-64) and this was supported by the evidence of a correlation between increased CpG/UpA and attenuation in our hamster models. However, the introduction of TCG trinucleotides affected the in vivo phenotype of YFV. In silico analysis predicted that such patterns are likely to be selected against in flaviviruses infecting vertebrates. In addition, studies on influenza virus produced evidence that CpG dinucleotides in an A/U context (e.g., TCG) may enhance virus detection by the host innate immune system (43, 44, 53) . Such trinucleotides can be used to induce a host-dependent attenuation, as recently demonstrated for dengue virus (70, 79) .
This study approach was exploratory. Hence, we chose to focus on the identification of mutations with low deleterious impact on in vivo replication and virulence of the yellow fever virus (YFV) rather than on the comprehensive characterization of the biological mechanisms underlying the attenuation process (e.g., protein translation, RNA replication, activation of innate immunity). Mechanistic insights on the specific effect(s) of the new re-encoding strategies would be most valuable, to gain insight into the finer details of viral attenuation and to facilitate fine-tuning of re-encoded viruses for the specific requirements of their intended use.
The initial aim of this exploratory work was to identify types of mutation with limited detrimental impact on viral replicative fitness, usable for large scale genome re-encoding. In this regard, "non-specific" transitions (i.e. with no CpG/UpA creation) represent the mutation type that best met our initial criteria. On this basis, we conclude that the introduction of transitions without CpG/UpA increase may constitute a ground rule for the custom-designed large-scale re-encoding of viral genomes. This does not rule out the possible use of mutations that increase the rate of CpG/UpA dinucleotides. We propose that using a limited number of such mutations may ensure that re-encoded genomes are relatively innocuous when tested in vivo, because these patterns ensure enhanced activation of host innate immunity. Thus, procedures combining large, pan-genomic non-specific re-encoding with limited bespoke CpG/UpA re-encoding should lead to the development of safe, stable and effective live-attenuated vaccine viruses with finely tuned phenotypes.
In addition to deciphering the mechanisms of attenuation, evaluating the stability of viral reencoded variants is a crucial objective for the development of vaccine candidates. Here, we observed no reversion to the parental Ap7M sequence of YFV re-encoded viruses when tested in vivo and virtually no reversion in vitro. However, for several re-encoded strains, the occurrence of consensus non-synonymous mutations in the sequences from the inoculum and/or hamster livers suggests that YFV re-encoded viruses may adapt and evolve both in vitro and in vivo. The molecular evolution of viral re-encoded strains has already been described for HIV and CHIKV-derived strains in vitro. The occurrence of synonymous and nonsynonymous consensus mutations correlated with partial recovery of (CHIKV) or full (HIV) WT replicative fitness (45, 72) . In accordance with the observations made on CHIKV evolution in vitro, some re-encoded strains retained a strongly attenuated phenotype that was not outweighed by the emergence of adaptative consensus mutations. Altogether, these elements suggest that, in some cases, the accumulation of slightly detrimental mutations could trap the virus, with no alternative mutational pathway with which to enable complete restoration of replicative fitness.
As illustrated by the case of poliovirus vaccines, live-attenuated vaccine strains have the potential to evolve following inoculation and in cases of dissemination following vaccination.
Hence, the development of re-encoded vaccine candidates should be accompanied by robust studies that address the potential fate of the variants in vivo. However, to the best of our knowledge, the evolutionary behaviour of re-encoded viruses in vivo has never been studied.
Since convenient in vivo laboratory models and reverse genetics systems are available, potential live attenuated YFV re-encoded vaccine candidates would provide a convenient experimental model for future in vivo studies. In the studies described above, we focused mainly on YF variants re-encoded in one specific region of the genome (NS2A-NS4B). These studies were appropriate for our experimental objectives but would not be ideal for evolution studies.
An optimized and more realistic design would rely on in vivo serial passage and deep sequencing characterization of evenly distributed synonymous mutations, along the entire genome, each with low fitness impact. The major objective would be to assess the stability of re-encoded strains with synonymously modified codon compositions and in particular, their potential to evolve towards modified phenotypes in vivo. 
Methods
Cells and animals
Viruses were produced in Baby hamster kidney BHK21 (ATCC, number CCL10) and Vero (ATCC, CCL81) cells and titrated in BHK21 cells. In vivo infection was performed in three-
week-old female Syrian Golden hamsters (Mesocricetus Auratus, Janvier and Charles River laboratories).
Ethics statement
Animal protocols were reviewed and approved by the ethics committee " 
Recovery of infectious viruses and stock production
All the strains used in this study (1 WT , 1 hamster-adapted and 17 re-encoded) were produced using the ISA method, that enables recovery of infectious viruses after transfection into permissive cells of overlapping subgenomic DNA fragments covering the entire genome (51) .
All fragment combination schemes used for virus production are detailed in Fig 1 and 
Nucleic acid extraction
Quantitative real-time RT-PCR assays
All quantitative real-time PCR (qRT-PCR) assays were performed using the EXPRESS SuperScript kit for One-Step qRT-PCR (Invitrogen) and the GoTaq® Probe 1-Step RT-qPCR System (Promega). Primers and probe sequences are detailed in the supplementary Table S6 .
The amount of viral RNA was calculated from standard curves using a synthetic RNA transcript (concentrations of 10 7 , 10 6 , 10 5 and 10 4 copies/μL). Results were normalised using amplification (qRT-PCR) of the housekeeping gene actin (as described by Piorkowski and colleagues (5) ). The standard curves generated for all the YFV-specific assays had coefficients of determination values (R2) >0,98 and amplification efficiencies were between 93% and 100%.
Competition assays
WT virus was grown in competition with each of the 9, Asibi-derived, re-encoded viruses using two RNA ratios in triplicate (WT/re-encoded virus: 
In vivo experiments
The laboratory hamster model reproduces the features of human YF but requires the use of adapted strains (7) . We recently implemented a hamster model for YFV, based on the use of a strain equivalent to the Asibi/hamster p7 strain described by Mac Arthur and colleagues in 2003 (8), Ap7M. When inoculated into hamsters, this strain induces a lethal viscerotropic disease similar to that described for YF Ap7 virus in terms of (i) clinical signs of illness, (ii) weight evolution, (iii) viral loads in the liver and (iv) lethality (100%). This strain was derived from Asibi by including 10 mutations in the FI subgenomic region used for viral recovery with the ISA method. As we chose to target the FII subgenomic region for re-encoding, the Ap7M strain was well suited for testing the effects of re-encoding on the biological properties of viruses in vivo.
Three-week-old female Syrian Golden hamsters were inoculated intra-peritoneally with 5. Liver samples were obtained from euthanised hamsters, ground and treated with proteinase K (PK) before nucleic acid extraction using either the EZ1 Biorobot or the QiaCube HT device (see corresponding section). Serum was recovered from euthanised hamsters and stored (-80°C).
Virus neutralisation assay
Sera were incubated for 20min at 56°C prior to viral serology. For each serum, serial 5-fold dilutions (first dilution: 1:250) of serum were tested on BHK21 cells for Ap7M strain infection inhibition. The plates were incubated for 44 hours before nucleic acid extraction. Virus quantification was achieved using the YFV-specific qRT-PCR system as described above.
Then, a viral RNA yield reduction (% of viral inhibition) was calculated for each well as follows:
−
With qYFVw the number of RNA copies in the analyzed well and qYFVm the mean number of RNA copies in the negative control wells. Fifty percent neutralisation titre NT50 values were determined from plots of % viral neutralisation versus serum dilutions and calculated by nonlinear regression (four-parameter dose-response curve) analysis using Graphpad PRISM software (v7.00 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com).
Whole and partial genome sequencing
Nucleotide sequences were determined using NGS methods: overlapping amplicons spanning either the complete genome sequence or a 256 nucleotides region (nucleotide positions: 4391-4646) were produced from the extracted RNA using the SuperScript® III One-Step RT-PCR System with Platinum®Taq High Fidelity kit (Invitrogen) and specific primers (detailed in the supplementary Table S7 ). Sequencing was performed using the PGM Ion torrent technology (Thermo Fisher Scientific) following the manufacturer's instructions.
Sequence determination. CDS consensus sequence determination was done using CLC genomics workbench software (CLC bio-Qiagen). Substitutions with a frequency higher than 5% were considered for the analysis of intra-population genetic diversity and major/minor variant subpopulations identification (minor variants: 5%< variants frequency <=75%; major variants: variants frequency >75%). No variant was taken into account with a coverage lower than 1000 reads. No consensus mutation was taken into account with a coverage lower than 50 reads.
Re-encoded virus quantification.
After sequencing the 256 nucleotide region using the PGM Ion torrent technology. Automated read datasets provided by Torrent software suite 5.0.2 were trimmed according to quality score using CLC genomics workbench software (CLC bio-Qiagen) and 6 re-encoded or wild-type specific patterns (see supplementary Tables S8, S9 and S10) were counted within the read datasets using in-house software. As a control, 2 patterns common to both viruses were counted to evaluate the total amount of virus for each sample.
Statistical analysis
Viral load comparisons were achieved using Wilcoxon rank-sum test with a continuity correction and Kaplan-Meier survival analysis, using Mandel-Cox's Logrank tests. Both analyses were performed using R software (6) . P-values below 0.05 were considered as significant. 
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